Q-omics provides the consensus-scored ZNF282 profile across patient tissues and cancer cell-line models. ZNF282 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ZNF282 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, ZNF282 RNA expression shows 19,798 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where ZNF282 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF282 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF282 survival associations across molecular data types. ZNF282 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF282 RNA expression–survival associations across cancer types. High ZNF282 expression shows unfavorable associations in ACC, MESO, COAD, LIHC and LUSC, but favorable associations in THYM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ZNF282 RNA expression.
This table summarizes ZNF282 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF282. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF282 shows higher tumor expression in HNSC, KIRC, KIRP, COAD, LIHC and BLCA. The HNSC box plot shows higher ZNF282 RNA expression in tumor versus normal tissue (log2 FC = +1.113, t-test p < 0.001).
This table shows molecular features associated with ZNF282 in patient tissues and cancer cell lines. In patient samples, ZNF282 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF282 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
